Core Viewpoint - CICC maintains the earnings forecast for Far East Horizon (03360) for 2025/2026 largely unchanged, with a target price increase of 10% to HKD 8.8 due to significant valuation discount and attractive dividend yield [1] Financial Performance - For 1H25, Far East Horizon reported a revenue decrease of 4% year-on-year to CNY 17.34 billion, while net profit attributable to shareholders increased by 4% to CNY 2.16 billion, achieving an annualized ROE of 8.66%, up 17 percentage points year-on-year, in line with expectations [2] - The company’s interim dividend payout ratio increased by 4 percentage points year-on-year to 50%, with a stable DPS of HKD 0.25, reflecting a slower growth in DPS compared to profit due to the dilution effect from convertible bonds [2] Financial Business - The financial business revenue for 1H25 increased by 2% year-on-year to CNY 11.09 billion, accounting for 64% of total revenue, with interest income slightly down by 0.4% to CNY 10.66 billion, while consulting fee income surged by 167% to CNY 430 million [3] - The net interest margin expanded, with net interest spread and net interest margin increasing by 11 basis points and 4 basis points year-on-year to 4.06% and 4.51%, respectively [3] - Asset quality remained stable, with non-performing loan ratio slightly decreasing by 0.02 percentage points to 1.05% and the provision coverage ratio remaining stable at 227% [3] Industrial Operations - The industrial operations segment saw a revenue decline of 13% year-on-year to CNY 6.33 billion, accounting for 37% of total revenue, with domestic business under pressure while overseas business experienced rapid growth [4] - The revenue from Hongxin Jianda decreased by 11% year-on-year to CNY 4.35 billion, with net profit down by 87% to CNY 35 million, affected by a decline in domestic market performance [4] - The healthcare segment, Hongxin Health, reported a 15% year-on-year decrease in hospital revenue to CNY 1.8 billion, with net profit down by 28% to CNY 110 million, as the company focuses on optimizing cost efficiency and expanding non-insurance business [4]

Core Viewpoint - Company maintains earnings forecasts for FY25/26 largely unchanged, with current trading at 0.67x/0.63x P/B for FY25/26, and a target price increase of 10% to HKD 8.8, reflecting a significant discount in valuation and attractive dividend yield [1] Financial Performance - For 1H25, company reported a revenue decline of 4% year-on-year to CNY 17.34 billion, while net profit attributable to shareholders increased by 4% to CNY 2.16 billion, achieving an annualized ROE of 8.66%, up 17 percentage points [2] - The dividend payout ratio increased by 4 percentage points year-on-year to 50%, with a stable DPS of HKD 0.25, indicating a slower growth in DPS compared to profit growth due to the dilution effect from convertible bonds [2] Financial Business - Financial business revenue grew by 2% year-on-year to CNY 11.09 billion, accounting for 64% of total revenue, with interest income down by 0.4% to CNY 10.66 billion and consulting fee income up by 167% to CNY 430 million [3] - The net interest margin expanded, with net interest spread and net interest margin increasing by 11 basis points and 4 basis points to 4.06% and 4.51%, respectively [3] - Asset quality remained stable, with non-performing loan ratio slightly decreasing by 0.02 percentage points to 1.05% and the provision coverage ratio remaining stable at 227% [3] Industrial Operations - Industrial operations revenue decreased by 13% year-on-year to CNY 6.33 billion, with a revenue share decline of 4 percentage points to 37% [4] - The overseas business of Hongxin Jianda experienced rapid growth, while domestic market downturn affected overall performance, with Jianda's revenue down 11% to CNY 4.35 billion and net profit down 87% to CNY 35 million [4] - The healthcare segment focused on optimizing management capabilities and cost efficiency, with hospital revenue down 15% to CNY 1.8 billion and net profit down 28% to CNY 110 million, while operational costs decreased by 11% to CNY 1.47 billion [4]

Core Viewpoint - Far East Horizon's 1H25 performance met expectations with a revenue decline of 4% year-on-year to 17.34 billion yuan and a net profit increase of 4% year-on-year to 2.16 billion yuan, resulting in an annualized ROE increase of 17 percentage points to 8.66% [1] Financial Performance - The company's financial business revenue increased by 2% year-on-year to 11.09 billion yuan, accounting for 64% of total revenue, with interest income slightly down by 0.4% to 10.66 billion yuan and consulting fee income up by 167% to 430 million yuan [1] - The net interest margin expanded with net interest spread and net interest margin increasing by 11 basis points and 4 basis points to 4.06% and 4.51% respectively, while asset quality remained stable with a non-performing loan ratio of 1.05% [1] Dividend Policy - The company increased its interim dividend payout ratio by 4 percentage points year-on-year to 50%, maintaining a dividend per share (DPS) of 0.25 HKD, indicating a strong dividend yield despite slower growth in DPS compared to profit growth due to dilution from convertible bonds [1] Industry Operations - The company's industrial operations revenue decreased by 13% year-on-year to 6.33 billion yuan, with a decline in domestic business offset by rapid growth in overseas operations [1] - The healthcare segment saw a revenue decline of 15% year-on-year to 1.8 billion yuan, with net profit down by 28% to 110 million yuan, as the company focused on optimizing cost efficiency and expanding non-insurance business [1] Valuation and Forecast - The company maintains its earnings forecast for 25/26e, currently trading at 0.67x/0.63x P/B for 25/26e, with a target price adjustment of 10% to 8.8 HKD, reflecting a significant discount in valuation and attractive dividend expectations [2]